Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 28

1.

High efficacy and safety of VTD as an induction protocol in patients with newly diagnosed multiple myeloma eligible for high dose therapy and autologous stem cell transplantation: A report of the Polish Myeloma Study Group.

Hus I, Mańko J, Jawniak D, Jurczyszyn A, Charliński G, Poniewierska-Jasak K, Usnarska-Zubkiewicz L, Sawicki M, Druzd-Sitek A, Świderska A, Kopińska A, Grząśko N, Raźny M, Wędłowska A, Perzyński A, Gałązka A, Dytfeld D, Kubicki T, Rodzaj M, Waszczuk-Gajda A, Drozd-Sokołowska J, Pogłódek B, Pasternak A, Długosz-Danecka M, Szymczyk A, Dmoszyńska A.

Oncol Lett. 2019 Dec;18(6):5811-5820. doi: 10.3892/ol.2019.10929. Epub 2019 Sep 27.

2.

International myeloma working group consensus recommendations on imaging in monoclonal plasma cell disorders.

Hillengass J, Usmani S, Rajkumar SV, Durie BGM, Mateos MV, Lonial S, Joao C, Anderson KC, García-Sanz R, Riva E, Du J, van de Donk N, Berdeja JG, Terpos E, Zamagni E, Kyle RA, San Miguel J, Goldschmidt H, Giralt S, Kumar S, Raje N, Ludwig H, Ocio E, Schots R, Einsele H, Schjesvold F, Chen WM, Abildgaard N, Lipe BC, Dytfeld D, Wirk BM, Drake M, Cavo M, Lahuerta JJ, Lentzsch S.

Lancet Oncol. 2019 Jun;20(6):e302-e312. doi: 10.1016/S1470-2045(19)30309-2. Review. Erratum in: Lancet Oncol. 2019 Jul;20(7):e346.

PMID:
31162104
3.

Efficacy of daratumumab monotherapy in real-world heavily pretreated patients with relapsed or refractory multiple myeloma.

Salomon-Perzyński A, Walter-Croneck A, Usnarska-Zubkiewicz L, Dytfeld D, Zielińska P, Wojciechowska M, Hołojda J, Robak P, Pasternak A, Knopińska-Posłuszny W, Hawrylecka D, Wójtowicz M, Szeremet A, Osowiecki M, Mordak-Domagała M, Zaucha JM, Giannopoulos K, Warzocha K, Jamroziak K.

Adv Med Sci. 2019 Sep;64(2):349-355. doi: 10.1016/j.advms.2019.05.001. Epub 2019 May 21.

PMID:
31125864
4.

Elotuzumab plus Pomalidomide and Dexamethasone for Multiple Myeloma.

Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, Leleu X, LeBlanc R, Suzuki K, Raab MS, Richardson PG, Popa McKiver M, Jou YM, Shelat SG, Robbins M, Rafferty B, San-Miguel J.

N Engl J Med. 2018 Nov 8;379(19):1811-1822. doi: 10.1056/NEJMoa1805762.

PMID:
30403938
5.

Real‑world multiple myeloma management practice patterns and outcomes in selected Central and Eastern European countries.

Coriu D, Dytfeld D, Niepel D, Spicka I, Markuljak I, Mihaylov G, Ostojic-Kolonic S, Fink L, Toka KS, Björklöf K.

Pol Arch Intern Med. 2018 Sep 28;128(9):500-511. doi: 10.20452/pamw.4305. Epub 2018 Jul 27. Erratum in: Pol Arch Intern Med. 2018 Dec 12;:null.

6.

Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma.

Rupa-Matysek J, Gil L, Barańska M, Dytfeld D, Komarnicki M.

Oncotarget. 2018 Apr 20;9(30):21190-21200. doi: 10.18632/oncotarget.25002. eCollection 2018 Apr 20.

7.

Natural history of relapsed myeloma, refractory to immunomodulatory drugs and proteasome inhibitors: a multicenter IMWG study.

Kumar SK, Dimopoulos MA, Kastritis E, Terpos E, Nahi H, Goldschmidt H, Hillengass J, Leleu X, Beksac M, Alsina M, Oriol A, Cavo M, Ocio EM, Mateos MV, O'Donnell EK, Vij R, Lokhorst HM, van de Donk NWCJ, Min C, Mark T, Turesson I, Hansson M, Ludwig H, Jagannath S, Delforge M, Kyriakou C, Hari P, Mellqvist U, Usmani SZ, Dytfeld D, Badros AZ, Moreau P, Kim K, Otero PR, Lee JH, Shustik C, Waller D, Chng WJ, Ozaki S, Lee JJ, de la Rubia J, Eom HS, Rosinol L, Lahuerta JJ, Sureda A, Kim JS, Durie BGM.

Leukemia. 2017 Nov;31(11):2443-2448. doi: 10.1038/leu.2017.138. Epub 2017 May 12.

PMID:
28620163
8.

Comparative proteomic profiling of sera from patients with refractory multiple myeloma reveals potential biomarkers predicting response to bortezomib-based therapy.

Łuczak M, Kubicki T, Rzetelska Z, Szczepaniak T, Przybyłowicz-Chalecka A, Ratajczak B, Czerwińska-Rybak J, Nowicki A, Joks M, Jakubowiak A, Komarnicki M, Dytfeld D.

Pol Arch Intern Med. 2017 Jun 30;127(6):392-400. doi: 10.20452/pamw.4032. Epub 2017 May 25.

9.

Glutaminase inhibitor CB-839 synergizes with carfilzomib in resistant multiple myeloma cells.

Thompson RM, Dytfeld D, Reyes L, Robinson RM, Smith B, Manevich Y, Jakubowiak A, Komarnicki M, Przybylowicz-Chalecka A, Szczepaniak T, Mitra AK, Van Ness BG, Luczak M, Dolloff NG.

Oncotarget. 2017 May 30;8(22):35863-35876. doi: 10.18632/oncotarget.16262.

10.

Clinical usefulness of serum free light chains measurement in patients with multiple myeloma: comparative analysis of two different tests.

Kubicki T, Dytfeld D, Baszczuk A, Wysocka E, Komarnicki M, Lewandowski K.

Postepy Hig Med Dosw (Online). 2017 Jan 4;71(0):40-46. doi: 10.5604/17322693.1229346.

11.

Chromosome 1 amplification has similar prognostic value to del(17p13) and t(4;14)(p16;q32) in multiple myeloma patients: analysis of real-life data from the Polish Myeloma Study Group.

Grzasko N, Hajek R, Hus M, Chocholska S, Morawska M, Giannopoulos K, Czarnocki K, Druzd-Sitek A, Pienkowska-Grela B, Rygier J, Usnarska-Zubkiewicz L, Dytfeld D, Kubicki T, Jurczyszyn A, Korpysz M, Dmoszynska A.

Leuk Lymphoma. 2017 Sep;58(9):1-15. doi: 10.1080/10428194.2016.1272684. Epub 2017 Jan 16. Erratum in: Leuk Lymphoma. 2017 Oct;58(10):2518.

PMID:
28092996
12.

Comparative proteomic profiling of refractory/relapsed multiple myeloma reveals biomarkers involved in resistance to bortezomib-based therapy.

Dytfeld D, Luczak M, Wrobel T, Usnarska-Zubkiewicz L, Brzezniakiewicz K, Jamroziak K, Giannopoulos K, Przybylowicz-Chalecka A, Ratajczak B, Czerwinska-Rybak J, Nowicki A, Joks M, Czechowska E, Zawartko M, Szczepaniak T, Grzasko N, Morawska M, Bochenek M, Kubicki T, Morawska M, Tusznio K, Jakubowiak A, Komarnicki MA.

Oncotarget. 2016 Aug 30;7(35):56726-56736. doi: 10.18632/oncotarget.11059.

13.

Synergistic Myeloma Cell Death via Novel Intracellular Activation of Caspase-10-Dependent Apoptosis by Carfilzomib and Selinexor.

Rosebeck S, Alonge MM, Kandarpa M, Mayampurath A, Volchenboum SL, Jasielec J, Dytfeld D, Maxwell SP, Kraftson SJ, McCauley D, Shacham S, Kauffman M, Jakubowiak AJ.

Mol Cancer Ther. 2016 Jan;15(1):60-71. doi: 10.1158/1535-7163.MCT-15-0488. Epub 2015 Dec 4.

14.

Efficacy and safety of lenalidomide treatment in multiple myeloma (MM) patients--Report of the Polish Myeloma Group.

Usnarska-Zubkiewicz L, Dębski J, Butrym A, Legieć W, Hus M, Dmoszyńska A, Stella-Hołowiecka B, Zaucha JM, Januszczyk J, Rymko M, Torosian T, Charliński G, Lech-Marańda E, Malenda A, Jurczyszyn A, Urbańska-Ryś H, Druzd-Sitek A, Błońska D, Urbanowicz A, Hołojda J, Pogrzeba J, Rzepecki P, Hałka J, Subocz E, Becht R, Zdziarska B, Dytfeld D, Nowicki A, Bołkun Ł, Kłoczko J, Knopińska-Posłuszny W, Zubkiewicz-Kucharska A, Kuliczkowski K.

Leuk Res. 2016 Jan;40:90-9. doi: 10.1016/j.leukres.2015.11.005. Epub 2015 Nov 15.

PMID:
26626207
15.

Proteomic profiling of naïve multiple myeloma patient plasma cells identifies pathways associated with favourable response to bortezomib-based treatment regimens.

Dytfeld D, Rosebeck S, Kandarpa M, Mayampurath A, Mellacheruvu D, Alonge MM, Ngoka L, Jasielec J, Richardson PG, Volchenboum S, Nesvizhskii AI, Sreekumar A, Jakubowiak AJ.

Br J Haematol. 2015 Jul;170(1):66-79. doi: 10.1111/bjh.13394. Epub 2015 Mar 30.

16.

Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma.

Dytfeld D, Jasielec J, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R, Jakubowiak AJ.

Haematologica. 2014 Sep;99(9):e162-4. doi: 10.3324/haematol.2014.110395. Epub 2014 Jun 27. No abstract available.

17.

Inhibitory effects of bortezomib on platelet aggregation in patients with multiple myeloma.

Rupa-Matysek J, Gil L, Wojtasińska E, Nowicki A, Dytfeld D, Kaźmierczak M, Komarnicki M.

Thromb Res. 2014 Aug;134(2):404-11. doi: 10.1016/j.thromres.2014.05.032. Epub 2014 Jun 2.

PMID:
24931724
18.

Second malignancies after autologous haematopoietic stem cell transplantation following modified BEAM conditioning regimen in patients with Hodgkin lymphoma - characteristics and risk factor analysis.

Czyż A, Lojko-Dankowska A, Matuszak M, Dytfeld D, Kaźmierczak M, Komarnicki M.

Contemp Oncol (Pozn). 2013;17(2):200-4. doi: 10.5114/wo.2013.34626. Epub 2013 Apr 29.

19.

Prognostic factors and long-term outcome of autologous haematopoietic stem cell transplantation following a uniform-modified BEAM-conditioning regimen for patients with refractory or relapsed Hodgkin lymphoma: a single-center experience.

Czyz A, Lojko-Dankowska A, Dytfeld D, Nowicki A, Gil L, Matuszak M, Kozlowska-Skrzypczak M, Kazmierczak M, Bembnista E, Komarnicki M.

Med Oncol. 2013;30(3):611. doi: 10.1007/s12032-013-0611-y. Epub 2013 May 24.

20.

Autologous stem cell transplantation as consolidation therapy for patients with peripheral T cell lymphoma in first remission: long-term outcome and risk factors analysis.

Czyz A, Romejko-Jarosinska J, Helbig G, Knopinska-Posluszny W, Poplawska L, Piatkowska-Jakubas B, Hawrylecka D, Nasilowska-Adamska B, Dytfeld D, Lojko-Dankowska A, Kopinska A, Boguradzki P, Walewski J, Kyrcz-Krzemien S, Hellmann A, Komarnicki M.

Ann Hematol. 2013 Jul;92(7):925-33. doi: 10.1007/s00277-013-1716-2. Epub 2013 Mar 8.

21.

Treatment strategy based on gemcitabine-containing salvage chemotherapy used with intent to proceed to second stem cell transplant for patients with Hodgkin lymphoma relapsing after a prior autologous transplant.

Czyz A, Romejko-Jarosinska J, Knopinska-Posluszny W, Nowicki A, Lojko-Dankowska A, Gil L, Dytfeld D, Walewski J, Hellmann A, Komarnicki M.

Leuk Lymphoma. 2013 May;54(5):973-8. doi: 10.3109/10428194.2012.734612. Epub 2012 Oct 29.

PMID:
23025342
22.

A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma.

Jakubowiak AJ, Dytfeld D, Griffith KA, Lebovic D, Vesole DH, Jagannath S, Al-Zoubi A, Anderson T, Nordgren B, Detweiler-Short K, Stockerl-Goldstein K, Ahmed A, Jobkar T, Durecki DE, McDonnell K, Mietzel M, Couriel D, Kaminski M, Vij R.

Blood. 2012 Aug 30;120(9):1801-9. doi: 10.1182/blood-2012-04-422683. Epub 2012 Jun 4.

24.

Activity of bortezomib in adult de novo and relapsed acute myeloid leukemia.

Gil L, Styczynski J, Dytfeld D, Debski R, Kazmierczak M, Kolodziej B, Rafinska B, Kubicka M, Nowicki A, Komarnicki M, Wysocki M.

Anticancer Res. 2007 Nov-Dec;27(6B):4021-5.

25.

[The role of the magnetic resonance in diagnosis of multiple myeloma].

Dytfeld D, Sosnowski P, Czyz A, Komarnick M.

Pol Merkur Lekarski. 2007 Aug;23(134):85-8. Polish.

PMID:
18044333
26.

Bortezomib in combination with thalidomide and dexamethasone--a successful treatment regimen in refractory extramedullary multiple myeloma.

Dytfeld D, Matuszak M, Lewandowski K, Komarnicki M.

Ann Hematol. 2008 Mar;87(3):253-4. Epub 2007 Oct 23. No abstract available.

PMID:
17955241
27.

[Ear lobe crease as a factor of potential risk for coronary artery disease?--World news review and own research].

Dytfeld D, Leśna J, Protasewicz A, Sarnowski W, Dyszkiewicz W, Paradowski S.

Pol Arch Med Wewn. 2002 Jul;108(1):633-8. Polish.

PMID:
12412407
28.

[Coronary artery fistula between pulmonary trunk and left descending coronary artery--description of two cases].

Dytfeld D, Sarnowski W.

Pol Merkur Lekarski. 2002 Jul;13(73):56-7. Polish.

PMID:
12362509

Supplemental Content

Loading ...
Support Center